NASH treatment: State of the art in 2020
Video NASH treatment: State of the art in 2020 -Copyright ©2023 by PanNash™ Initiative - All rights reserved.
NASH treatment: State of the art in 2020
Would you like to read more?
Prof. M. F. Abdelmalek
Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase…
Cardiovascular Disease in MASLD Patients: Mitigating Risks
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease…
Geographical burden of NAFLD: a review
Over the past few decades, non-alcoholic fatty liver disease (NAFLD) has become a growing problem, alongside the increasing rates of…
Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus…
Understanding Nash: Symptoms, Detection, And Treatment
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in…
An exploration of MAFLD’s clinical utility
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty…
NAFLD and New-Onset Heart Failure: What is the Link?
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Adipose tissue insulin resistance and fibrosis stage in NASH
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance…
Adverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
NAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18%…
The Power of PPARs in NASH-associated Microvascular Dysfunction
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty…
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
